Emisphere (NASDAQ:EMIS) is an emerging bio-pharma company specializing in the development of a drug delivery technology platform for the oral administration of therapeutic compounds which are either poorly absorbed or must be given through alternative routes such as injections.   On 6/1/09, EMIS announced that Novartis (NYSE:NVS) and Nordic Bioscience have completed recruitment for the planned second multi-center Phase 3 study exploring the safety and efficacy of an oral

More: continued here